Elon Musk’s ketamine use excluded from OpenAI fraud trial

The ongoing legal battle between Elon Musk and OpenAI represents far more than a personal dispute between two tech titans—it signals fundamental questions about corporate governance, intellectual property rights, and the future trajectory of artificial intelligence development that should concern every European investor with exposure to AI markets. Recent developments in the Oakland federal court, where U.S. District Judge Yvonne Gonzalez Rogers ruled that certain personal matters would remain inadmissible in the fraud trial, underscore how high-stakes litigation over foundational AI technologies is likely to shape the regulatory environment across global markets, including Europe. **The Core Dispute and Its Implications** Musk's lawsuit against OpenAI and Microsoft centers on allegations that the organization departed from its original non-profit mission, transforming into a de facto for-profit venture controlled by Microsoft. This fundamental disagreement about corporate structure and mission drift carries significant implications for European investors evaluating AI sector opportunities. The case raises critical questions: What constitutes appropriate governance in AI companies receiving substantial government and private capital? How should intellectual property developed under one corporate structure be treated if that structure fundamentally changes? For European entrepreneurs and institutional investors, this litigation establishes a cautionary precedent. As the European Union continues developing its